336 related articles for article (PubMed ID: 15483014)
21. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma.
Weng WK; Weng WK; Levy R
Leuk Lymphoma; 2009 Sep; 50(9):1494-500. PubMed ID: 19672774
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
23. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
Leitch HA; Connors JM
Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
[TBL] [Abstract][Full Text] [Related]
24. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy.
Weng WK; Czerwinski D; Levy R
Blood; 2007 Feb; 109(3):951-3. PubMed ID: 17032925
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
Redfern CH; Guthrie TH; Bessudo A; Densmore JJ; Holman PR; Janakiraman N; Leonard JP; Levy RL; Just RG; Smith MR; Rosenfelt FP; Wiernik PH; Carter WD; Gold DP; Melink TJ; Gutheil JC; Bender JF
J Clin Oncol; 2006 Jul; 24(19):3107-12. PubMed ID: 16754937
[TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster Trial NHL-BFM 95.
Seidemann K; Zimmermann M; Book M; Meyer U; Burkhardt B; Welte K; Reiter A; Stanulla M
J Clin Oncol; 2005 Nov; 23(33):8414-21. PubMed ID: 16293872
[TBL] [Abstract][Full Text] [Related]
27. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
Vose J
Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
[TBL] [Abstract][Full Text] [Related]
28. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
[TBL] [Abstract][Full Text] [Related]
29. Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination.
Cesco-Gaspere M; Zentilin L; Giacca M; Burrone OR
Scand J Immunol; 2008 Jul; 68(1):58-66. PubMed ID: 18482206
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
Savelyeva N; King CA; Vitetta ES; Stevenson FK
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10987-92. PubMed ID: 16037207
[TBL] [Abstract][Full Text] [Related]
31. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
Kube D; Hua TD; von Bonin F; Schoof N; Zeynalova S; Klöss M; Gocht D; Potthoff B; Tzvetkov M; Brockmöller J; Löffler M; Pfreundschuh M; Trümper L
Clin Cancer Res; 2008 Jun; 14(12):3777-84. PubMed ID: 18559596
[TBL] [Abstract][Full Text] [Related]
32. Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)/V(H) determinants.
Benvenuti F; Burrone OR
Gene Ther; 2001 Oct; 8(20):1555-61. PubMed ID: 11704816
[TBL] [Abstract][Full Text] [Related]
33. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.
Tobinai K; Ogura M; Kobayashi Y; Uchida T; Watanabe T; Oyama T; Maruyama D; Suzuki T; Mori M; Kasai M; Cronier D; Wooldridge JE; Koshiji M
Cancer Sci; 2011 Feb; 102(2):432-8. PubMed ID: 21205069
[TBL] [Abstract][Full Text] [Related]
35. FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.
Wang B; Kokhaei P; Mellstedt H; Liljefors M
Int J Oncol; 2010 Dec; 37(6):1599-606. PubMed ID: 21042730
[TBL] [Abstract][Full Text] [Related]
36. Fc gamma RIIa, IIIa and IIIb polymorphisms in Turkish children susceptible to recurrent infectious diseases.
Ozturk C; Aksu G; Berdeli A; Kutukculer N
Clin Exp Med; 2006 Mar; 6(1):27-32. PubMed ID: 16550341
[TBL] [Abstract][Full Text] [Related]
37. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.
Klapper W; Hoster E; Rölver L; Schrader C; Janssen D; Tiemann M; Bernd HW; Determann O; Hansmann ML; Möller P; Feller A; Stein H; Wacker HH; Dreyling M; Unterhalt M; Hiddemann W; Ott G;
J Clin Oncol; 2007 Aug; 25(22):3330-6. PubMed ID: 17664481
[TBL] [Abstract][Full Text] [Related]
38. The role of idiotype vaccines in the treatment of human B-cell malignancies.
Bendandi M
Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
[TBL] [Abstract][Full Text] [Related]
39. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development.
Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Zabalegui N; Villanueva H; Bendandi M
Crit Rev Oncol Hematol; 2004 Oct; 52(1):1-7. PubMed ID: 15363462
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of idiotypic vaccination in mice bearing B-cell lymphoma.
Khan NA
In Vivo; 1989; 3(2):117-9. PubMed ID: 2519837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
